Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

mRNA-binding protein tristetraprolin is essential for cardiac response to iron deficiency by regulating mitochondrial function.

Sato T, Chang HC, Bayeva M, Shapiro JS, Ramos-Alonso L, Kouzu H, Jiang X, Liu T, Yar S, Sawicki KT, Chen C, Martínez-Pastor MT, Stumpo DJ, Schumacker PT, Blackshear PJ, Ben-Sahra I, Puig S, Ardehali H.

Proc Natl Acad Sci U S A. 2018 Jun 18. pii: 201804701. doi: 10.1073/pnas.1804701115. [Epub ahead of print]

PMID:
29915044
2.

Amino Acid Restriction Triggers Angiogenesis via GCN2/ATF4 Regulation of VEGF and H2S Production.

Longchamp A, Mirabella T, Arduini A, MacArthur MR, Das A, Treviño-Villarreal JH, Hine C, Ben-Sahra I, Knudsen NH, Brace LE, Reynolds J, Mejia P, Tao M, Sharma G, Wang R, Corpataux JM, Haefliger JA, Ahn KH, Lee CH, Manning BD, Sinclair DA, Chen CS, Ozaki CK, Mitchell JR.

Cell. 2018 Mar 22;173(1):117-129.e14. doi: 10.1016/j.cell.2018.03.001.

PMID:
29570992
3.

The mTORC1 Signaling Network Senses Changes in Cellular Purine Nucleotide Levels.

Hoxhaj G, Hughes-Hallett J, Timson RC, Ilagan E, Yuan M, Asara JM, Ben-Sahra I, Manning BD.

Cell Rep. 2017 Oct 31;21(5):1331-1346. doi: 10.1016/j.celrep.2017.10.029.

4.

Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells.

Lam HC, Liu HJ, Baglini CV, Filippakis H, Alesi N, Nijmeh J, Du H, Lope AL, Cottrill KA, Handen A, Asara JM, Kwiatkowski DJ, Ben-Sahra I, Oldham WM, Chan SY, Henske EP.

Oncotarget. 2017 Aug 4;8(39):64714-64727. doi: 10.18632/oncotarget.19947. eCollection 2017 Sep 12.

5.

The energy disruptor metformin targets mitochondrial integrity via modification of calcium flux in cancer cells.

Loubiere C, Clavel S, Gilleron J, Harisseh R, Fauconnier J, Ben-Sahra I, Kaminski L, Laurent K, Herkenne S, Lacas-Gervais S, Ambrosetti D, Alcor D, Rocchi S, Cormont M, Michiels JF, Mari B, Mazure NM, Scorrano L, Lacampagne A, Gharib A, Tanti JF, Bost F.

Sci Rep. 2017 Jul 11;7(1):5040. doi: 10.1038/s41598-017-05052-2.

6.

mTORC1 signaling and the metabolic control of cell growth.

Ben-Sahra I, Manning BD.

Curr Opin Cell Biol. 2017 Apr;45:72-82. doi: 10.1016/j.ceb.2017.02.012. Epub 2017 Apr 12. Review.

7.

The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.

Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K.

Nat Med. 2017 Mar;23(3):301-313. doi: 10.1038/nm.4283. Epub 2017 Feb 13.

8.

mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle.

Ben-Sahra I, Hoxhaj G, Ricoult SJH, Asara JM, Manning BD.

Science. 2016 Feb 12;351(6274):728-733. doi: 10.1126/science.aad0489.

9.

Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation.

Covarrubias AJ, Aksoylar HI, Yu J, Snyder NW, Worth AJ, Iyer SS, Wang J, Ben-Sahra I, Byles V, Polynne-Stapornkul T, Espinosa EC, Lamming D, Manning BD, Zhang Y, Blair IA, Horng T.

Elife. 2016 Feb 19;5. pii: e11612. doi: 10.7554/eLife.11612.

10.

Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP.

Ricoult SJ, Yecies JL, Ben-Sahra I, Manning BD.

Oncogene. 2016 Mar 10;35(10):1250-60. doi: 10.1038/onc.2015.179. Epub 2015 Jun 1.

11.

ZBTB7A acts as a tumor suppressor through the transcriptional repression of glycolysis.

Liu XS, Haines JE, Mehanna EK, Genet MD, Ben-Sahra I, Asara JM, Manning BD, Yuan ZM.

Genes Dev. 2014 Sep 1;28(17):1917-28. doi: 10.1101/gad.245910.114.

12.

Low-dose radiation exposure induces a HIF-1-mediated adaptive and protective metabolic response.

Lall R, Ganapathy S, Yang M, Xiao S, Xu T, Su H, Shadfan M, Asara JM, Ha CS, Ben-Sahra I, Manning BD, Little JB, Yuan ZM.

Cell Death Differ. 2014 May;21(5):836-44. doi: 10.1038/cdd.2014.24. Epub 2014 Feb 28.

13.

Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia.

Rosilio C, Ben-Sahra I, Bost F, Peyron JF.

Cancer Lett. 2014 May 1;346(2):188-96. doi: 10.1016/j.canlet.2014.01.006. Epub 2014 Jan 22. Review.

PMID:
24462823
14.

The TSC-mTOR pathway regulates macrophage polarization.

Byles V, Covarrubias AJ, Ben-Sahra I, Lamming DW, Sabatini DM, Manning BD, Horng T.

Nat Commun. 2013;4:2834. doi: 10.1038/ncomms3834.

15.

A growing role for mTOR in promoting anabolic metabolism.

Howell JJ, Ricoult SJ, Ben-Sahra I, Manning BD.

Biochem Soc Trans. 2013 Aug;41(4):906-12. doi: 10.1042/BST20130041. Review.

PMID:
23863154
16.

Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1.

Ben-Sahra I, Howell JJ, Asara JM, Manning BD.

Science. 2013 Mar 15;339(6125):1323-8. doi: 10.1126/science.1228792. Epub 2013 Feb 21.

17.

Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death.

Ben-Sahra I, Dirat B, Laurent K, Puissant A, Auberger P, Budanov A, Tanti JF, Bost F.

Cell Death Differ. 2013 Apr;20(4):611-9. doi: 10.1038/cdd.2012.157. Epub 2012 Dec 14.

18.

Prevention of mutagenesis: new potential mechanisms of metformin action in neoplastic cells.

Bost F, Ben-Sahra I, Tanti JF.

Cancer Prev Res (Phila). 2012 Apr;5(4):503-6. doi: 10.1158/1940-6207.CAPR-12-0085.

19.

Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.

Puissant A, Dufies M, Fenouille N, Ben Sahra I, Jacquel A, Robert G, Cluzeau T, Deckert M, Tichet M, Chéli Y, Cassuto JP, Raynaud S, Legros L, Pasquet JM, Mahon FX, Luciano F, Auberger P.

J Mol Cell Biol. 2012 Aug;4(4):207-20. doi: 10.1093/jmcb/mjs010. Epub 2012 Mar 31.

PMID:
22467682
20.

Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF, Giorgetti-Peraldi S, Bost F.

Cancer Res. 2011 Jul 1;71(13):4366-72. doi: 10.1158/0008-5472.CAN-10-1769. Epub 2011 May 3.

21.

The combination of metformin and 2 deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells.

Ben Sahra I, Tanti JF, Bost F.

Autophagy. 2010 Jul 1;6(5):670-671. doi: 10.4161/auto.6.5.12434.

PMID:
28157435
22.
23.

Metformin in cancer therapy: a new perspective for an old antidiabetic drug?

Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F.

Mol Cancer Ther. 2010 May;9(5):1092-9. doi: 10.1158/1535-7163.MCT-09-1186. Epub 2010 May 4. Review.

24.

Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.

Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, Deckert M, Auberger P, Tanti JF, Bost F.

Cancer Res. 2010 Mar 15;70(6):2465-75. doi: 10.1158/0008-5472.CAN-09-2782. Epub 2010 Mar 9.

25.

Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death.

Robert G, Ben Sahra I, Puissant A, Colosetti P, Belhacene N, Gounon P, Hofman P, Bost F, Cassuto JP, Auberger P.

PLoS One. 2009 Nov 18;4(11):e7889. doi: 10.1371/journal.pone.0007889.

26.

Hypoxia decreases insulin signaling pathways in adipocytes.

Regazzetti C, Peraldi P, Grémeaux T, Najem-Lendom R, Ben-Sahra I, Cormont M, Bost F, Le Marchand-Brustel Y, Tanti JF, Giorgetti-Peraldi S.

Diabetes. 2009 Jan;58(1):95-103. doi: 10.2337/db08-0457. Epub 2008 Nov 4.

27.

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F.

Oncogene. 2008 Jun 5;27(25):3576-86. doi: 10.1038/sj.onc.1211024. Epub 2008 Jan 21.

PMID:
18212742

Supplemental Content

Loading ...
Support Center